Compare ClearPoint Neuro Inc (CLPT) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Medpace Holdings Inc — how do they compare? ClearPoint Neuro Inc trades at $15.87 (market cap $478.63M), while Medpace Holdings Inc trades at $535.48 (market cap $15.31B). The key difference: Medpace Holdings Inc is far larger — about 32× ClearPoint Neuro Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | MEDP | |
|---|---|---|
Market Cap | $478.63M | $15.31B |
Sector | Health | Technology |
52-Week High | $29.60 | $620.59 |
52-Week Low | $8.66 | $308.88 |
Enterprise Value | $506.63M | $14.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
MEDP trades at $530.19, down 1.49% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected on July 22, 2026. Fundamentals show robust profitability with a 17.19% net income margin and 77.25% ROE, though valuation ratios like P/E of 33.74 are elevated. Recent news highlights volatility and a class action lawsuit filed in June 2026.
Outlook is mixed; earnings momentum and high profitability support upside, but high valuation and legal overhang pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term gains. Investors should weigh strong operational performance against valuation concerns and litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
